All In Biotech

Drug Trial Radar · NCT03034915

A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Mar 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 2,696 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,696

Actual

Start

Jun 16, 2017

Primary completion

Jun 18, 2018

Study completion Jun 18, 2018

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

COPD is characterized by an airflow limitation, which is not fully reversible, usually progressive and accompanied by chronic cough, sputum production and dyspnea, which can be a major cause of disability and anxiety associated with the disease. In addition, COPD is associated with poor health-related quality of life (HRQoL). Pharmacologic therapy is used to improve lung function, reduce symptoms, reduce the frequency and severity of exacerbations, and also to improve health status and exercise tolerance. This is a multi-center, randomized, double blind, double dummy, 3-arm parallel group study to compare umeclidinium/vilanterol (62.5/25 microgram \[mcg\], once daily), umeclidinium (62.5 mcg, once daily), and salmeterol (50 mg, twice daily) in male and female subjects with COPD. The primary purpose of this study is to demonstrate improvements in lung function for subjects treated with UMEC/VI compared with UMEC for 24 weeks. Approximately 2424 subjects will be randomized across 3 parallel arms in 1:1:1 ratio. Subjects will be stratified based on long-acting bronchodilator usage during the run-in period (none, one or 2 long-acting bronchodilators per day). Subjects will receive either UMEC/VI inhalation powder (62.5/25 microgram \[mcg\] once daily) administered via the ELLIPTA® dry powder inhaler (DPI) and placebo twice daily via DISKUS® DPI; or UMEC (62.5 mcg once daily) administered via the ELLIPTA DPI and placebo twice daily via DISKUS DPI or salmeterol (50 mcg twice daily \[BID\]) administered via the DISKUS DPI and placebo once daily via ELLIPTA DPI. The duration of the study will be 29 to 31 weeks including a pre-screening period of 2 weeks, run-in period of 4 weeks, treatment period of 24 weeks and follow-up period of 1 week. ELLIPTA and DISKUS are trademarks of GSK group of companies.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • UMEC/VI 62.5/25 mcg via ELLIPTADrug

    ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.

  • UMEC 62.5 mcg via ELLIPTADrug

    The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).

  • Salmeterol 50 mcg via DISKUSDrug

    The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.

  • Placebo via ELLIPTADrug

    Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.

  • Placebo via DISKUSDrug

    Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) at Week 24Time frame: Baseline (Pre-dose on Day 1) and Week 24

Locations

212 sites in 12 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Lincoln, California

  • GSK Investigational Site

    Clearwater, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    O'Fallon, Illinois

  • GSK Investigational Site

    Natchitoches, Louisiana

  • GSK Investigational Site

    Edina, Minnesota

  • GSK Investigational Site

    Fridley, Minnesota

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Woodbury, Minnesota

  • GSK Investigational Site

    Chesterfield, Missouri

  • GSK Investigational Site

    Saint Charles, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Omaha, Nebraska

  • GSK Investigational Site

    Albuquerque, New Mexico

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Gastonia, North Carolina

  • GSK Investigational Site

    Monroe, North Carolina

  • GSK Investigational Site

    Mooresville, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Medford, Oregon

  • GSK Investigational Site

    Anderson, South Carolina

  • GSK Investigational Site

    Charleston, South Carolina

  • GSK Investigational Site

    Easley, South Carolina

  • GSK Investigational Site

    Gaffney, South Carolina

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Lancaster, South Carolina

  • GSK Investigational Site

    Mt. Pleasant, South Carolina

  • GSK Investigational Site

    Rock Hill, South Carolina

  • GSK Investigational Site

    Seneca, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Union, South Carolina

  • GSK Investigational Site

    Sherman, Texas

  • GSK Investigational Site

    Abingdon, Virginia

  • GSK Investigational Site

    Morgantown, West Virginia

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

Showing 40 of 212 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.